Insilico Medicine is testing a Traf2‐ and Nck‐interacting protein kinase (TNIK) inhibitor in the context of kidney fibrosis as well as the prolyl hydroxylases (PHD)1/2 inhibitor for anemia in chronic kidney disease. This evidence concerns the gene EGLN2 and anemia (phenotype).